Pancreatic Cancer Research

ResearcherThe Royal Melbourne HospitalActive in the last 2 years

Belinda Lee

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0002-0947-9834; OpenAlex author ID A5054979658, A5076387746, A5122224647. Sources: OpenAlex.

Their work

Papers
27 (first author 4, last author 7)
Trials
0
Grants
0
Labs led
1
Collaborators
73
Papers, trials and grants by year

2019: 3 papers · 2020: none · 2021: 3 papers · 2022: 3 papers · 2023: 5 papers · 2024: 4 papers · 2025: 4 papers · 2026: 5 papers

Papers 27

  1. Endoscopic ultrasound molecular evaluation of pancreatic cancer trial to profile molecular landscape of inoperable pancreatic ductal adenocarcinoma. Co-author DOI 10.1055/a-2733-1068↗
  2. Prognostic value of KRAS gene mutations in pancreatic ductal adenocarcinoma: a systematic review and meta-analysis. First author DOI 10.1080/00365521.2025.2610630↗
  3. Predicting recurrence patterns and outcomes following resection of pancreatic ductal adenocarcinoma: a contemporary real-world data cohort study. Last author DOI 10.1097/ms9.0000000000004919↗
  4. Systematic Review and Meta-Analysis of Current and Novel Approaches in the Management of Borderline Resectable and Locally Advanced Pancreatic Cancer. Last author DOI 10.3390/cancers18071139↗
  5. Decision support tools for pancreatic cancer detection: external validation in Australian primary care - a retrospective cohort study. Co-author DOI 10.3399/bjgp.2025.0328↗
  6. Skeletal muscle and visceral fat density are predictive imaging biomarkers for overall survival in patients with pancreatic adenocarcinoma: A retrospective mul… Co-author DOI 10.1016/j.suronc.2025.102251↗
  7. Neoadjuvant Chemotherapy With Chemoradiotherapy for Patients With Borderline Resectable or Locally Advanced Pancreatic Ductal Adenocarcinoma-Retrospective Revi… Co-author DOI 10.1111/ajco.14166↗
  8. A Scoping Review on the Data Utility, Clinical Impact, and Cost of Multidisciplinary Team Meetings for Pancreatic Cancer. Co-author DOI 10.1111/ans.70262↗
  9. Exploring the association between Cultural and Linguistic Diversity (CALD) on treatment and outcomes in pancreatic cancer: an analysis of PURPLE real-world reg… First author DOI 10.1186/s12889-025-23925-4↗
  10. Impact of neoadjuvant FOLFIRINOX over upfront resection in borderline resectable pancreatic cancer-an international, multicentre, real-world analysis. Last author DOI 10.1016/j.esmorw.2023.100022↗
  11. Early onset pancreatic cancer-exploring contemporary treatment and outcomes using real-world data. Last author DOI 10.1038/s41416-024-02619-5↗
  12. Addressing disparities in health outcomes for patients with advanced pancreatic cancer and limited English proficiency. Last author DOI 10.1111/ajco.14076↗
  13. Evolution of Liquid Biopsies for Detecting Pancreatic Cancer. Last author DOI 10.3390/cancers16193335↗
  14. Current state of radiomic research in pancreatic cancer: focusing on study design and reproducibility of findings. Co-author DOI 10.1007/s00330-023-09653-6↗
  15. ASCEND: a randomised, double-blinded, placebo-controlled, phase II study of gemcitabine and nab-paclitaxel with LSTA1 in untreated metastatic pancreatic adenoc… Co-author DOI 10.1016/j.esmogo.2023.07.001↗
  16. S100 family proteins are linked to organoid morphology and EMT in pancreatic cancer. Co-author DOI 10.1038/s41418-023-01126-z↗
  17. Correction to: S100 family proteins are linked to organoid morphology and EMT in pancreatic cancer. Co-author DOI 10.1038/s41418-023-01151-y↗
  18. Use and outcomes from neoadjuvant chemotherapy in borderline resectable pancreatic ductal adenocarcinoma in an Australasian population. First author DOI 10.1111/ajco.13807↗
  19. Treatment and outcomes of unresectable and metastatic pancreatic cancer treated in public and private Australian hospitals. Last author DOI 10.1111/ajco.13721↗
  20. Real-world staging computed tomography scanning technique and important reporting discrepancies in pancreatic ductal adenocarcinoma. Co-author DOI 10.1111/ans.17787↗
  21. Use and outcomes of chemotherapy for metastatic pancreatic cancer in Australia. Co-author DOI 10.1111/imj.15094↗
  22. A Histone Deacetylase Inhibitor, Panobinostat, Enhances Chimeric Antigen Receptor T-cell Antitumor Effect Against Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-21-1141↗
  23. The Diverse Applications of Pancreatic Ductal Adenocarcinoma Organoids. Co-author DOI 10.3390/cancers13194979↗
  24. The EUS molecular evaluation of pancreatic cancer: A prospective multicenter cohort trial. Co-author DOI 10.4103/eus-d-20-00230↗
  25. Circulating tumor DNA as a potential marker of adjuvant chemotherapy benefit following surgery for localized pancreatic cancer. Co-author DOI 10.1093/annonc/mdz200↗
  26. Inflammation, Biomarkers and Immuno-Oncology Pathways in Pancreatic Cancer. Co-author DOI 10.3390/jpm9020020↗
  27. Clinical Applications of Circulating Tumour DNA in Pancreatic Adenocarcinoma. First author DOI 10.3390/jpm9030037↗

Closest collaborators

The 25 strongest of 73 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Peter Gibbs · 17 shared papers, 2019–2026 · strength 3.13
  2. Benjamin N. J. Thomson · 8 shared papers, 2019–2025 · strength 1.27
  3. Benjamin P. T. Loveday · 6 shared papers, 2022–2026 · strength 1.19
  4. Mehrdad Nikfarjam · 6 shared papers, 2019–2026 · strength 0.94
  5. Hyun Soo Ko · 4 shared papers, 2022–2025 · strength 0.79
  6. Daniel Gerald Croagh · 3 shared papers, 2021–2026 · strength 0.72
  7. Matthew Burge · 5 shared papers, 2019–2026 · strength 0.72
  8. Sean Michael Grimmond · 4 shared papers, 2021–2026 · strength 0.65
  9. Adnan M. Nagrial · 4 shared papers, 2019–2024 · strength 0.51
  10. Shehara Ramyalini Mendis · 3 shared papers, 2022–2025 · strength 0.51
  11. Yat Hang To · 3 shared papers, 2022–2024 · strength 0.47
  12. Adrian M. Fox · 3 shared papers, 2023–2024 · strength 0.45
  13. Marion Harris · 4 shared papers, 2019–2023 · strength 0.43
  14. Ronnie Ren Jie Low · 3 shared papers, 2021–2023 · strength 0.42
  15. Tracy L. Putoczki · 3 shared papers, 2021–2023 · strength 0.42
  16. Henry Shen · 1 shared paper, 2026 · strength 0.39
  17. Saeed Aslani · 1 shared paper, 2026 · strength 0.39
  18. Ryan B. Munnings · 1 shared paper, 2024 · strength 0.36
  19. Kelvin Le · 1 shared paper, 2026 · strength 0.36
  20. Prasad D. Cooray · 3 shared papers, 2019–2023 · strength 0.35
  21. Sam Banks · 2 shared papers, 2024–2025 · strength 0.34
  22. Margaret Lee · 2 shared papers, 2022–2025 · strength 0.33
  23. Rachel Ε. Neale · 1 shared paper, 2026 · strength 0.33
  24. Javiera Martínez-Gutiérrez · 1 shared paper, 2026 · strength 0.33
  25. Silja Schrader · 1 shared paper, 2026 · strength 0.33

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.